Column 1 Column 1Column 1Column 1 [/table][/table] Column 1...

	Column 1
1	Column 1 Column 1 Column 1

[/table][/table][/table]
[/table][/table]

	Column 1
1	Column 1 Column 1

[/table][/table]
[/table]

	Column 1
1	Column 1

[/table]
[/table][/table]

Column 1

1

Column 1 Column 1 Zero Safety Issues for IMU’s Immunotherapy Cancer Treatment: Phase II Trial Imminent​ Clinical stage life sciences company Imugene (ASX:IMU) is on the cutting edge of immunotherapy, developing vaccines to boost and direct the immune system to target and attack cancer cells.​ IMU’s HER-Vaxx is a drug candidate designed to produce an antibody response against a cancer growth signal receptor protein called HER-2, found on the cell surface in breast and gastric cancers.​ Recently completed Phase I/b trials successfully tested three doses of HER-Vaxx, in combination with current standard of care chemotherapy. Importantly, Phase I/b showed zero safety issues and all dose levels generated antibody responses in patients.​ Preparations are now underway to advance to Phase II of the HER-Vaxx Stomach Cancer Immuno-oncology Trial, beginning early 2019. Regulatory submissions are underway, and full Phase I/b results are expected next month.​

[/table][/table]
[/table]

In addition to HER-Vaxx, IMU has acquired two new assets through a licencing program with Ohio State University and Mayo Clinic – Key-Vaxx and B-Vaxx.
B-Vaxx and KEY-Vaxx are of particular interest as clinical candidates for IMU, and it has big plans to put KEY-Vaxx through the next stage of clinical trials in 2019 in its goal to create the pre-eminent, dominant position globally in B-cell peptide vaccines and therapeutics.
To become the dominant player, IMU has also added plenty of highly credentialed and well connected top new talent to support its ambitions.
With new products and players, IMU has grown and matured in the last 12 months and, from where we stand, looks to have plenty more growth to come.​

	Column 1
1	Column 1

[/table]